drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular therapy (CAR γδ T cells)
drug_description
A gene-modified cellular therapy of gamma-delta (γδ) T cells engineered with a BCMA-targeted chimeric antigen receptor (CAR). Administered as a single infusion to treat relapsed/refractory multiple myeloma by recognizing BCMA (TNFRSF17) on malignant plasma cells and mediating MHC-independent cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gamma-delta T cells engineered with a BCMA-targeted CAR bind BCMA (TNFRSF17) on myeloma cells, triggering MHC-independent activation and cytotoxicity (perforin/granzyme release, cytokine secretion, proliferation) to eliminate BCMA+ malignant plasma cells.
drug_name
UTAA17 Injection
nct_id_drug_ref
NCT06279026